Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer

[1]  M. Ychou,et al.  Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. , 2022, JAMA oncology.

[2]  Y. Inoue,et al.  Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with Videos) , 2022, Annals of Surgical Oncology.

[3]  C. V. van Eijck,et al.  Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. , 2021, European journal of cancer.

[4]  Y. Nagakawa,et al.  New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS) , 2021, Journal of hepato-biliary-pancreatic sciences.

[5]  Y. Iwashita,et al.  Surgical and oncological outcomes of laparoscopic versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma , 2021, Surgery Today.

[6]  G. Honda,et al.  Surgical approaches for minimally invasive distal pancreatectomy: A systematic review , 2021, Journal of hepato-biliary-pancreatic sciences.

[7]  S. Yagi,et al.  Left-posterior approach for artery-first en bloc resection in laparoscopic distal pancreatectomy for left-sided pancreatic cancer , 2020, Langenbeck's Archives of Surgery.

[8]  Taiping Zhang,et al.  Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrospective study , 2020, Surgical Endoscopy.

[9]  Y. Kawabata,et al.  Laparoscopic versus open radical antegrade modular pancreatosplenectomy with artery–first approach in pancreatic cancer , 2020, Langenbeck's Archives of Surgery.

[10]  E. Rosso,et al.  Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Venous Tangential Resection: Focus on Periadventitial Dissection of the Superior Mesenteric Artery for Obtaining Negative Margin and a Safe Vascular Resection , 2020, Annals of Surgical Oncology.

[11]  E. Jensen,et al.  Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival , 2019, Annals of Surgical Oncology.

[12]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  T. Sato,et al.  Possible underestimation of blood loss during laparoscopic hepatectomy , 2019, BJS open.

[14]  M. Dijkgraaf,et al.  Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. , 2019, The lancet. Gastroenterology & hepatology.

[15]  V. Lemmens,et al.  Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis , 2018, Acta oncologica.

[16]  K. Kawamoto,et al.  Laparoscopic radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer using the ligament of Treitz approach , 2017, Surgical Endoscopy.

[17]  A. Saiura,et al.  Left kidney mobilization technique during radical antegrade modular pancreatosplenectomy (RAMPS) , 2017, Langenbeck's Archives of Surgery.

[18]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[19]  J. Cameron,et al.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.

[20]  D. Gouma,et al.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.

[21]  K. Uesaka,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer , 2017 .

[22]  T. Hong,et al.  Initial experience with laparoscopic radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer in a single institution: technical aspects and oncological outcomes , 2017, BMC Surgery.

[23]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[24]  T. Ohtsuka,et al.  Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sided Pancreatic Cancer , 2016, World Journal of Surgery.

[25]  K. Kichikawa,et al.  Importance of resectability status in neoadjuvant treatment for pancreatic cancer , 2015, Journal of hepato-biliary-pancreatic sciences.

[26]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[27]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[28]  R. Fields,et al.  Left-Sided Pancreatic Cancer: Distal Pancreatectomy and its Variants Radical Antegrade Modular Pancreatosplenectomy and Distal Pancreatectomy With Celiac Axis Resection , 2012, Cancer journal.

[29]  D. Gouma,et al.  Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). , 2007, Surgery.

[30]  Abe Fingerhut,et al.  Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. , 2007, Surgery.

[31]  W. Hawkins,et al.  Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. , 2007, Journal of the American College of Surgeons.

[32]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[33]  J. Drebin,et al.  Radical antegrade modular pancreatosplenectomy. , 2003, Surgery.

[34]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[35]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[36]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[37]  M. Kanda,et al.  Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting , 2016, Journal of Gastroenterology.

[38]  S. Choi,et al.  Role of Radical Antegrade Modular Pancreatosplenectomy for Adenocarcinoma of the Body and Tail of the Pancreas , 2013, World Journal of Surgery.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[40]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.